calcifediol - Profile

What are the generic drug sources for calcifediol and what is the scope of patent protection?

Calcifediol is the generic ingredient in two branded drugs marketed by Eirgen and Organon Usa Inc, and is included in two NDAs. There are sixteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Calcifediol has one hundred and ninety-two patent family members in thirty-eight countries.

Summary for calcifediol

International Patents:	192
US Patents:	16
Tradenames:	2
Applicants:	2
NDAs:	2

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for calcifediol

Dosage:

CAPSULE, EXTENDED RELEASE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for calcifediol

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Eirgen	RAYALDEE	calcifediol	CAPSULE, EXTENDED RELEASE;ORAL	208010-001	Jun 17, 2016		RX	Yes	Yes
Eirgen	RAYALDEE	calcifediol	CAPSULE, EXTENDED RELEASE;ORAL	208010-001	Jun 17, 2016		RX	Yes	Yes
Eirgen	RAYALDEE	calcifediol	CAPSULE, EXTENDED RELEASE;ORAL	208010-001	Jun 17, 2016		RX	Yes	Yes
Eirgen	RAYALDEE	calcifediol	CAPSULE, EXTENDED RELEASE;ORAL	208010-001	Jun 17, 2016		RX	Yes	Yes			Y
Eirgen	RAYALDEE	calcifediol	CAPSULE, EXTENDED RELEASE;ORAL	208010-001	Jun 17, 2016		RX	Yes	Yes
Eirgen	RAYALDEE	calcifediol	CAPSULE, EXTENDED RELEASE;ORAL	208010-001	Jun 17, 2016		RX	Yes	Yes
Eirgen	RAYALDEE	calcifediol	CAPSULE, EXTENDED RELEASE;ORAL	208010-001	Jun 17, 2016		RX	Yes	Yes			Y

Expired US Patents for calcifediol

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Organon Usa Inc	CALDEROL	calcifediol	CAPSULE;ORAL	018312-001	Approved Prior to Jan 1, 1982
Eirgen	RAYALDEE	calcifediol	CAPSULE, EXTENDED RELEASE;ORAL	208010-001	Jun 17, 2016
Organon Usa Inc	CALDEROL	calcifediol	CAPSULE;ORAL	018312-001	Approved Prior to Jan 1, 1982
Organon Usa Inc	CALDEROL	calcifediol	CAPSULE;ORAL	018312-002	Approved Prior to Jan 1, 1982
Organon Usa Inc	CALDEROL	calcifediol	CAPSULE;ORAL	018312-002	Approved Prior to Jan 1, 1982

International Patents for calcifediol

Country	Patent Number	Title	Estimated Expiration
Spain	2401205
Denmark	2968172
Slovenia	3335712
South Korea	20170004018	비타민 Ｄ 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물 (ORAL CONTROLLED RELEASE COMPOSITIONS COMPRISING VITAMIN D COMPOUND AND WAXY CARRIER)
Cyprus	1125077
European Patent Office	2481400	Compositions orales à libération contrôlée comprenant des composés de vitamine D et un véhicule cireux (Oral controlled release compositions comprising vitamin D compound and waxy carrier)
Eurasian Patent Organization	201991774

Supplementary Protection Certificates for calcifediol

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2481400	CA 2020 00059	Denmark		PRODUCT NAME: CALCIFEDIOL; NAT. REG. NO/DATE: 62564 20200910; FIRST REG. NO/DATE: UK PL 50784/0005-0001 20200721
2481400	122020000079	Germany		FORMER OWNERS: OPKO IRELAND GLOBAL HOLDINGS, LTD., DUBLIN 24, IE; OPKO RENAL, LLC, MIAMI, FL 33137, US
2481400	C202130022	Spain		PRODUCT NAME: CALCIFEDIOL; NATIONAL AUTHORISATION NUMBER: 85519-DE/H/5590/001/DC; DATE OF AUTHORISATION: 20201230; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): DE/H/5590/001/DC; DATE OF FIRST AUTHORISATION IN EEA: 20200721
2968172	SPC/GB20/043	United Kingdom		PRODUCT NAME: CALCIFEDIOL, AND/OR A SALT OR HYDRATE THEREOF, IN PARTICULAR CALCIFEDIOL MONOHYDRATE; REGISTERED: UK PL 50784/0005-0001 20200721
2481400	132021000000071	Italy		PRODUCT NAME: CALCIFEDIOLO(RAYALDEE); AUTHORISATION NUMBER(S) AND DATE(S): 047870011, 20201201;PL 50784/0005, 20200721
2968172	122021000009	Germany		PRODUCT NAME: CALCIFEDIOL UND/ODER PHARMAZEUTISCH AKZEPTABLE SALZE UND HYDRATE DAVON, BEVORZUGT CALCIFEDIOLMONOHYDRAT; REGISTRATION NO/DATE: 2202115.00.00 20200818
2968172	301095	Netherlands		PRODUCT NAME: CALCIFEDIOL IN IEDERE VORM ZOALS BESCHERMD DOOR HET BASISOCTROOI; NATIONAL REGISTRATION NO/DATE: 124799 20200922; FIRST REGISTRATION: DE 2202115.00.00 20200819

Analysis of Calcifediol (25-Hydroxyvitamin D3): Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

---

Summary

Calcifediol (25-Hydroxyvitamin D3) has garnered significant attention due to its emerging therapeutic applications, notably in vitamin D deficiency management and potential roles in musculoskeletal, immune, and metabolic health. The compound's unique pharmacokinetics, advantages over conventional vitamin D supplements, and regulatory considerations position it as a promising asset within the pharmaceutical landscape. This report evaluates the current market landscape, investment potential, competitive dynamics, regulatory framework, and financial forecast for calcifediol from 2023 onward.

---

1. What Is Calcifediol and Why Is It Gaining Attention?

Calcifediol is the pre-hormone form of vitamin D, produced in the liver from cholecalciferol (vitamin D3). It is a potent, rapid-acting vitamin D analogue with higher bioavailability compared to standard vitamin D supplements (vitamin D3 or ergocalciferol). Its potential clinical advantages include:

• Faster correction of vitamin D deficiency.
• More predictable pharmacokinetics, especially in patients with malabsorption or liver disease.
• Greater potency, reducing dosing frequency and improving patient compliance.

Clinical applications are expanding in indications such as osteoporosis, rickets, autoimmune disorders, and potentially COVID-19-related immune regulation (Barnes et al., 2020).

---

2. Market Drivers and Demand Trends

Factor	Impact on Market	Details
Rising Vitamin D Deficiency Prevalence	Globally high deficiency rates (estimated at >40%), especially in older populations.	Driven by lifestyle, geographic latitude, and aging populations[1].
Clinical Evidence Supporting Efficacy	Studies demonstrate faster correction and better serum levels with calcifediol.	Recent trials (e.g., Powe et al., 2019) affirm benefits.
Preference in Special Populations	Malabsorptive patients, liver disease, and seniors benefit from calcifediol.	Forms of supplementation tailored for these groups.

• Global vitamin D supplement market estimated to reach USD 1.2 billion (2022), growing at 7% CAGR (Grand View Research, 2022).
• Calcifediol segment poised for accelerated growth within this market, driven by clinical evidence and regulatory support.

---

3. Competitive Landscape and Key Players

Company	Product Name	Status	Market Focus	Notes
Sanofi	-	Pre-market, clinical trials	Supplement and prescription uses	Advanced in clinical development[2]
Theramex	Calcifediol	Approved in Europe	Prescription drug in osteoporosis	Marketed explicitly for vitamin D deficiency
Chodera	Custom formulations	Early development	Pharmaceutical and supplement sectors	Focus on bioavailability enhancement
Others	CD101 (circular pathway)	Emerging players	Generic manufacturing, bioavailability	Entry through licensing and biosimilars[3]

Major Market Segments:

• Prescription drugs: Especially in Europe and emerging markets.
• Over-the-counter (OTC) products: Limited, but potential given demand for high-dose formulations.
• Nutraceuticals: Growth driven by dietary supplement industry.

---

4. Regulatory Landscape Impact

Region	Status of Calcifediol	Regulatory Pathway	Notes
European Union (EU)	Approved as a medicinal product in some countries	EMA approval, national marketing authorizations	e.g., Theramex’s calcifediol products
United States (US)	Not yet approved; classified as dietary supplement or drug	FDA proceeding with Investigational New Drug (IND)	Recent clinical trials could expedite approval pathways
Asia-Pacific	Varying degrees of approval, limited by regulatory backlog	Local agency approvals	Growing markets with increasing vitamin D deficiency

Key regulatory hurdles:

• Demonstrating bioequivalence or therapeutic efficacy.
• Ensuring safety, especially with high-dose formulations.
• Clarification of classification (drug vs. supplement) affects market scope.

---

5. Market Projections and Financial Trajectory

Parameter	2023	2025	2030	Notes
Global calcifediol market size	USD 150M	USD 400M	USD 1.2B	CAGR approximately 15-20% driven by clinical adoption and regulatory approvals type.
Key Revenue Streams	Prescription (~70%), OTC (~20%), Nutraceuticals (~10%)	-	-	Growth driven by expanding indications and formulations.
Investment Opportunities	High for early-stage developers, licensing, and manufacturing	-	-	Especially in bioavailability technology and novel formulations.
R&D Investment Needed	USD 20-50M	USD 50-100M	USD 100-300M	For clinical trials, regulatory filing, and market entry.

Financial drivers include:

• Accelerated clinical trials demonstrating efficacy.
• Strategic licensing deals with large pharma.
• Cost-efficient manufacturing innovations.

---

6. Comparative Analysis: Calcifediol versus Vitamin D3 Supplements

Attribute	Calcifediol	Vitamin D3 (Cholecalciferol)	Implication
Bioavailability	Higher (~4x)	Lower, depends on absorption	Faster correction and predictable serum levels
Onset of Action	Rapid	Slow	Suitable for deficiency correction
Dosing Frequency	Lower	Higher	Better compliance potential
Regulatory Status	Prescription or approved in some regions	Widely OTC	Market penetration varies
Cost	>10x	Lower	Price-sensitive markets may favor D3

---

7. Challenges and Risks

Risk Factor	Impact	Mitigation Strategy
Regulatory Delays	Slower market entry	Early engagement with regulators, robust clinical data
Competition from Existing Supplements	Market share dilution	Differentiation through clinical efficacy and formulations
Manufacturing Scalability	Supply constraints	Investment in scalable, cost-efficient production facilities
Patent Expiry & Generic Entry	Price erosion	Strategic patent filings and lifecycle management
Clinical Uncertainty	Adoption hesitance	Publishing peer-reviewed studies, real-world evidence

---

8. Strategic Recommendations for Investors

Action Point	Rationale	Expected Outcome
Invest in clinical-stage companies	Demonstrated safety and efficacy needed for growth	Capitalize on regulatory approvals
Focus on bioavailability technology	Differentiation and patent protection	Competitive advantage
Engage in licensing agreements	Accelerates market access and reduces costs	Faster ROI and risk mitigation
Monitor regulatory developments	Critical for timing product launches	Better market entry planning

---

9. Key Comparisons with Similar Drugs

Drug	Indication	Market Size (USD)	Regulatory Status	Unique Advantage
Calcifediol	Vitamin D deficiency, osteoporosis	USD 150M (2023 est.)	Approved in EU, emerging in US	Faster correction, higher potency
Calcitriol	Hypocalcemia, secondary hyperparathyroidism	USD 200M	Approved worldwide	Active form, but with higher toxicity risk
Cholecalciferol	General supplementation	USD 1.2B	OTC	Cost-effective, widely used

---

10. Future Outlook and Market Penetration

• Potential for expanding indications: Autoimmune diseases, COVID-19 related immune modulation, certain cancers.
• Market adoption factors: Clinical validation, regulatory approvals, cost competitiveness.
• Supply chain: Scalability through biosynthesis and synthetic pathways.
• Integration into clinical practice: Education of healthcare providers on benefits.

---

Key Takeaways

• Calcifediol's pharmacological profile offers significant advantages over traditional vitamin D3, particularly in speed and potency, creating high-growth potential in the vitamin D supplement and pharmaceutical markets.
• Market growth is driven by rising global deficiency rates, evolving indications, and positive clinical evidence, especially in Europe where approved drug products are marketed.
• Investment opportunities exist primarily in clinical development, licensing, and bioavailability technologies, with the potential for rapid advancement upon regulatory approval.
• Regulatory pathways remain complex; early engagement and robust clinical data are essential to navigate approval processes efficiently.
• Competitive positioning depends on differentiation through efficacy, safety, and formulation capabilities, with cost management pivotal for market penetration.

---

FAQs

1. What is the primary therapeutic advantage of calcifediol over traditional vitamin D supplements?
Calcifediol rapidly increases serum 25-hydroxyvitamin D levels with fewer doses, offering predictable pharmacokinetics beneficial for patients with absorption or metabolic issues.

2. Which regions offer the most promising regulatory environment for calcifediol products?
Europe currently has the most advanced regulatory framework with approved calcifediol medications. The US is progressing toward approval through ongoing clinical trials and IND applications.

3. What are potential barriers to market entry for calcifediol products?
Regulatory approval delays, competition from established vitamin D products, manufacturing scale-up costs, and patent challenges pose significant barriers.

4. How does calcifediol market growth compare to the overall vitamin D supplement market?
Calcifediol is projected to grow faster (~15-20% CAGR) owing to clinical advantages, whereas the overall vitamin D supplement market grows at around 7%. Its niche positioning within the broader market enhances its growth prospects.

5. Which companies are poised to benefit most from calcifediol market expansion?
Companies with clinical pipeline advances (e.g., Theramex, Sanofi), proprietary formulations, and licensing capabilities are strategically well-positioned as the market expands.

---

References

[1] Grand View Research. (2022). Vitamin D Market Size, Share & Trends Analysis Report.
[2] International Journal of Clinical Practice. (2020). "Clinical Trials of Calcifediol."
[3] Regulatory Affairs Professionals Society. (2022). "Global Pathways for Vitamin D Analog Drugs."
[4] Barnes et al. (2020). "Vitamin D and Immune Function in COVID-19." Journal of Autoimmunity.

---

Note: This analysis aggregates current data and projections as of early 2023. Market dynamics and regulatory landscapes may evolve, impacting financial trajectories.